Tansel Çakır

Tansel Çakır

Auto-generated profile, based on publicly available information

Tansel Çakır

Department of Nuclear Medicine, İstanbul Medipol University Faculty of Medicine, İstanbul, Türkiye

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2022 in Breast Care
Verified
Journal Article
Open access
PDF file
SASabin Goktas Aydin
Sabin Goktas Aydin
ABAhmet Bilici
Ahmet Bilici
OOOmer Fatih Olmez
Omer Fatih Olmez
BOBasak B. Oven
Basak B. Oven
OAOzgur Acikgoz
Ozgur Acikgoz
JHJamshid Hamdard
Jamshid Hamdard
Purpose: Patients with locally advanced breast cancer (LABC) should be treated with neoadjuvant chemotherapy (NAC). Pathological complete response (pCR) is related to better disease-free survival (DFS). The best strategy for assessing the efficacy of NAC has not been established yet, but several studies have shown that 18F-FDG PET/CT is a potential imaging tool for assessing pCR. The aim of this study is to investigate the merits of 18F-FDG PET/CT imaging in predicting pCR in both axillary and breast tissue and to establish a threshold maximum standard uptake value (SUVmax) for predicting the response after completion of NAC. Methods: A total of 186 LABC patients, treated with an NAC regimen according to tumor subtype, were retrospectively analyzed in this study. All patients underwent 18F-FDG PET/CT imaging before and after completion of NAC. PET parameters were measured in the most FDG avid breast tissue and axillary lymph nodes. We analyzed the correlation between the tumor SUVmax of the PET/CT response and the pCR after surgery. DFS was also evaluated with respect to pCR. Results: Higher pCR rates were significantly associated with a higher tumor grade, an initial Ki-67 ≥20% (p = 0.03 and p = 0.003, respectively), a triple-negative subtype (32.9%), and a human epidermal growth factor receptor 2 (HER-2)-positive subtype (24.7%) (p < 0.001). There was a significant correlation between the pCR and a complete response in 18F-FDG PET/CT (p < 0.001). The overall sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of 18F-FDG PET/CT to determine the pCR after NAC were 100%, 72.2%, 85%, 75.2%, and 100%, respectively. We demonstrated a 1.1 cutoff SUVmax for breast tumors after NAC (OR: 3.94, 95% CI: 1.14–5.05, p = 0.004), the 18F-FDG PET/CT response to NAC (OR: 0.50, 95% CI: 0.25–0.99, p = 0.003), and the molecular subtype of breast tumors (OR: 0.58, 95% CI: 0.38–0.88, p = 0.011). Conclusion: Our results confirm that 18F-FDG PET/CT is a useful method for predicting the NAC response in LABC.


26 August 2020 in Nuclear Medicine Seminars
Verified
Journal Article
Closed access
ÜAÜmit Özgür Akdemir
Ümit Özgür Akdemir
LALütfiye Özlem Atay
Lütfiye Özlem Atay
FAFunda Aydın
Funda Aydın
TÇTansel Çakır
Tansel Çakır
MKMeryem Kaya
Meryem Kaya
OYOlga Yaylalı
Olga Yaylalı


25 September 2026 in OncoImmunology
Verified
Journal Article
Open access
MYMEHMET HALUK YÜCEL
MEHMET HALUK YÜCEL
MMMartin Mildanoğlu
Martin Mildanoğlu
EDEbru engin delipoyraz
Ebru engin delipoyraz
HÖHakan Özçelik
Hakan Özçelik
ESErdem Sünger
Erdem Sünger
ABAhmet Bilici
Ahmet Bilici
1. Despite the addition of immune checkpoint inhibitors (ICIs) to platinum-etoposide as first-line therapy, extensive-stage small cell lung cancer (ES-SCLC) remains a highly lethal disease, with a ...

31 December 2022 in Acta Medica Alanya
Verified
Journal Article
Open access
EÖEce Özdemi̇r Öktem
Ece Özdemi̇r Öktem
KSKübra Soğukkanli
Kübra Soğukkanli
TÇTansel Çakir
Tansel Çakir
AÖAhmet Özşimşek
Ahmet Özşimşek
ŞÇŞeyda Çankaya
Şeyda Çankaya
LHLütfü Hanoğlu
Lütfü Hanoğlu
Aim: To investigate the clinical characteristics and cerebral FDG PET metabolisms of dementia patients who were also diagnosed with epilepsy and compare the differences with pure Alzheimer dementia patients.Methods: In this case-control study, a total of 14 patients, 7 patients with pure Alzheimer disease as a control group and 7 age and gender-matched patients with Alzheimer disease and concomitant epilepsy as a study group, were included. Detailed neurocognitive battery and brain fludeoxyglucose positron emission tomography (FDG PET-CT) were performed for all subjects.Results: In comparison of neurocognitive test scores, there was no significant difference between the study and control groups. However, geriatric depression scale scores were significantly lower in study group than the controls (p= 0.026). In cerebral FDG-PET CT profiles of subjects we detected significantly lower metabolism in left and right cerebellum, left lentiform nucleus, right thalamus and vermis in the study group (p=0.008, p=0.023, p=0.003, p=0.002, p=0.002, respectively). In the right parietotemporal cortex and right and left associative visual cortex, we found higher metabolism in the study group than controls (p=0.023, p=0.012, p=0.003, respectively).Conclusion: Epileptic patients with Alzheimer’s dementia may have distinct clinical and metabolic profiles, than pure Alzheimer’s disease patients. Even if there is no difference in the neurocognitive clinical scores of the patients, depression and related functional abnormalities may be a biomarker of epileptic AD.